Complement-targeted therapy: development of C5- and C5a-targeted inhibition

Inflammation and Regeneration

Volumn 36, Issue 1, 2016, Pages

  Horiuchi, Takahiko ^a   Tsukamoto, Hiroshi ^b  

^a KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

C5; C5a; C5a receptor; Complement; Membrane attack complex

Indexed keywords

EID: 85012083842     PISSN: None     EISSN: 18808190     Source Type: Journal    
DOI: 10.1186/s41232-016-0013-6     Document Type: Article

References (31)

1. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol. 2013;190:3831–8.
2. Tsukamoto H, Horiuchi T. Clinical aspects of the complement system. Rinsho Byori. 2006;54:757–62.
3. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355:1233–43.
4. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360:544–6.
5. Matis LA, Rollins SA. Complement-specific antibodies: designing novel anti-inflammatories. Nat Med. 1995;1:839–42.
6. Jayne DR, Bruchfeld A, Schaier M, et al. Oral C5a receptor antagonist CCX168 phase II clinical trial in ANCA-associated renal vasculitis. Ann Rheum Dis. 2014;73 Suppl 2:148. abstract.
7. Bekker P, Jayne D, Bruchfeld A, et al. CCX168, an orally administered C5aR inhibitor for treatment of patients with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2014;66:S820. abstract.
8. Horiuchi T, Mitoma H, Harashima S-I, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215–28.
9. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells. Arthritis Rheum. 2008;58:1248–57.
10. Horiuchi T, Ohi H, Ohsawa I, et al. Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research—secondary publication. Allergol Int. 2012;61:559–62.
11. Reis ES, Mastellos DC, Yancopoulou D, et al. Applying complement therapeutics to rare diseases. Clin Immunol. 2015;161:225–40.
12. Brodsky RA. Complement in hemolytic anemia. Blood. 2015;126:2459–65.
13. Kaplan BS, Ruebner RL, Spinale JM, et al. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34–45.
14. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8:622–33.
15. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol. 2011;48:1631–42.
16. Jose PJ, Moss IK, Maini RN, et al. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis. 1990;49:747–52.
17. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis—a genomewide study. N Engl J Med. 2007;357:1199–209.
18. Nishimoto K, Kochi Y, Ikari K, et al. Association study of TRAF1-C5 polymorphism with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese. Ann Rheum Dis. 2010;69:368–73.
19. Johansson AC, Sundler M, Kjellen P, et al. Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Eur J Immunol. 2001;31:1847–56.
20. Lindqvis AK, Johannesson M, Johansson AC, et al. Backcross and partial advanced intercross analysis of nonobese diabetic gene-mediated effects on collagen-induced arthritis reveals an interactive effect by two major loci. J Immunol. 2006;177:3952–9.
21. Wang Y, Kristan J, Hao L, et al. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J Immunol. 2000;164:4340–7.
22. Ji H, Gauquier D, Ohmura K, et al. Genetic influences on the end-stage effector phase of arthritis. J Exp Med. 2001;194:321–30.
23. Vergunst CE, Gerlag DM, Dinant H, et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford). 2007;46:1773–8.
24. Mojcik CF, Kremer J, Bingham C, et al. Results of a phase 2b study of the humanized anti-C5 antibody eculizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63 Suppl 1:301. abstract.
25. Yuan J, Gou SJ, Huang J, et al. C5a and its receptors in human antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther. 2012;14:R140.
26. Gou S-J, Yuan J, Chen M, et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2012;83:129–37.
27. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170:52–64.
28. Huugen D, van Esch A, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71:646–54.
29. Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25:225–31.
30. Klos A, Tenner AJ, Johswich K-O, et al. The role of the anaphylatoxins in health and disease. Mol Immunol. 2009;46:2753–66.
31. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013;190:3839–47.